Next Generation Immunoassay Analyzer Boasts Industry’s Highest Throughput per Footprint

Now, an innovation-packed immunoassay analyzer will enable labs across the globe to improve their throughput rates and turnaround times with unparalleled precision.

Beckman Coulter (Brea, CA, USA) has introduced the DxI 9000 Access immunoassay analyzer, the most efficient immunoassay analyzer per footprint capable of conducting up to 215 tests per hour per square meter (tests/hr/m2). The DxI 9000 Access incorporates innovations designed to address current demands for speed, dependability, reproducibility, quality, and menu expansion. These advancements improve assay performance and lab productivity, incorporating new technologies for analyte processing and detection, precision sensors, smart algorithms, and real-time system monitoring.

The DxI 9000 Access stands alone as the only immunoassay analyzer that requires no daily maintenance. Its ZeroDaily Maintenance feature emphasizes the embedded innovations that enhance the analyzer's uptime performance. Beta users have endorsed ZeroDaily Maintenance for transforming their workday by eliminating daily maintenance needs, consequently reducing annual maintenance routines by up to 96%. The DxI 9000 Access also incorporates PrecisionVision Technology, which is unrivaled in its capacity to inspect, identify, and prevent incorrect reporting in real time. Its automated safeguards include tube identification, cap detection, tip check, sample aspiration, and delivery, residual wash volume, and substrate volume. Each check mitigates the risk of reporting inaccurate data and boosts system reliability and reproducibility.

Beckman Coulter's newly developed remote service and diagnostic solution, DxS IntelliServe, interfaces with DxI 9000 Analyzers to track data and error patterns, facilitating proactive system servicing when required. The DxS IntelliServe solution also identifies service experts to resolve issues via real-time monitoring, remote operation, and troubleshooting, thereby maximizing lab uptime and performance. Furthermore, IntelliServe's remote update features and proactive scheduling ensure systems are always utilizing the latest software, minimizing unexpected workflow disruptions or downtime.

Beckman Coulter's Access NT-proBNP assay measures the concentration of N-terminal pro B-type natriuretic peptide originating from a person's heart. Elevated levels of natriuretic peptides can signal heart failure. Access NT-proBNP provides swift results in under 11 minutes and enhances accuracy in diagnosing heart failure with age-based cutoffs and disease-specific comorbidity data for superior test result interpretation. This platform has been independently validated to perform at the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) optimal level, the highest level of EFLM performance evaluation. Simultaneously, the new Lumi-Phos PRO Substrate has demonstrated the potential to develop increasingly sensitive and clinically relevant assays, ensuring the system's readiness to meet future healthcare requirements. The DxI 9000 Access Immunoassay Analyzer is currently available in most countries worldwide.

“The DxI 9000 Access Immunoassay Analyzer sets new expectations for immunoassay testing operational performance and ability to develop and sustain improved assay sensitivity to meet tomorrow's analytical needs,” said Julie Sawyer Montgomery, President, Beckman Coulter Diagnostics. “Those in the laboratory will treasure ZeroDaily Maintenance to save them time, PrecisionVision Technology to safeguard against flawed data reports, and IntelliServe to maximize system uptime. At the same time, clinical researchers are excited about the DxI 9000 Analyzer's capability to keep pace with increasingly sensitive testing requirements as healthcare providers and pharmaceutical companies take aim at ever more challenging diseases. An inspiring feat of technology, the DxI 9000 Analyzer is a comprehensive healthcare innovation.”

Related Links:
Beckman Coulter